Related Experiment Video
Updated: Jul 16, 2025
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
11.7K
Myelofibrosis: diagnosis and treatment
Gilberto Barranco-Lampón1,2, Raúl Martínez-Castro3, Luara Arana-Luna4
1Servicio de Hematología, Hospital General de México, Ciudad de México, México.
Gaceta Medica De Mexico
|September 21, 2023
Summary
Myelofibrosis (MF) is a blood cancer. Janus kinase (JAK) inhibitors like ruxolitinib treat symptoms, but stem cell transplant is the only cure. New treatments are under investigation.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm.
- Characterized by clonal myeloproliferation, dysregulated kinase signaling, and abnormal cytokine release.
- Conventional treatments offer limited survival benefits.
Purpose of the Study:
- To review the molecular biology and prognostic assessment of Myelofibrosis.
- To discuss current and emerging therapeutic strategies for MF.
- To highlight the role of Janus kinase (JAK) inhibitors and allogeneic stem cell transplantation.
Main Methods:
- Literature review of Myelofibrosis pathogenesis and treatment.
- Analysis of conventional therapies including symptomatic management and cytoreductive drugs.
- Evaluation of targeted therapies, focusing on JAK inhibitors and stem cell transplantation.
Main Results:
- Janus kinase (JAK) 2 mutation discovery led to targeted therapies.
- JAK inhibitors, such as ruxolitinib, are effective for MF symptoms and splenomegaly.
- Allogeneic stem cell transplantation is the only curative option but is limited by risks.
Conclusions:
- Ruxolitinib has improved MF management but lacks disease-modifying effects.
- Combination therapies and novel drug investigations are ongoing to enhance treatment outcomes.
- Allogeneic stem cell transplantation remains the sole curative approach for eligible MF patients.
